NCT03277352

INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies

A Phase 1/2 Safety and Efficacy Study of INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies

• Status: Terminated
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 10 (actual)
• Sponsor: Incyte Biosciences International Sàrl · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine the safety, tolerability, and efficacy of INCAGN01876 when given in combination with immune therapies.

Conditions

• Advanced Malignancies
• Metastatic Cancer

Interventions

Type	Name	Description
DRUG	INCAGN01876	In Phase 1 subjects will receive INCAGN01876 administered intravenously (IV) at the protocol-defined dose and schedule according to cohort and treatment group enrollment. In Phase 2, subjects will be administered IV study drug at the recommended dose from Phase 1.
DRUG	Epacadostat	Epacadostat will be self-administered orally at the protocol-defined dose.
DRUG	Pembrolizumab	Pembrolizumab will be administered IV at the protocol-defined dose.

Timeline

• Start date: 2017-11-21
• Primary completion: 2020-07-01
• Completion: 2020-07-01
• First posted: 2017-09-11
• Last updated: 2021-07-22
• Results posted: 2021-07-22

Locations

2 sites across 1 country: United States

Regulatory

• FDA-regulated drug study